Initial experience of enfortumab vedotin in a patient with metastatic urothelial carcinoma on hemodialysis: Two case reports

Q4 Medicine

IJU Case Reports Pub Date : 2024-05-26 DOI:10.1002/iju5.12736

Shintaro Mori, Tomohiro Matsuo, Hiroyuki Honda, Kyohei Araki, Kensuke Mitsunari, Kojiro Ohba, Yasushi Mochizuki, Ryoichi Imamura

{"title":"Initial experience of enfortumab vedotin in a patient with metastatic urothelial carcinoma on hemodialysis: Two case reports","authors":"Shintaro Mori, Tomohiro Matsuo, Hiroyuki Honda, Kyohei Araki, Kensuke Mitsunari, Kojiro Ohba, Yasushi Mochizuki, Ryoichi Imamura","doi":"10.1002/iju5.12736","DOIUrl":null,"url":null,"abstract":"<div>\n \n <section>\n \n <h3> Introduction</h3>\n \n <p>Few studies have reported on administering enfortumab vedotin to patients with metastatic urothelial carcinoma and end-stage renal disease requiring hemodialysis.</p>\n </section>\n \n <section>\n \n <h3> Case presentation</h3>\n \n <p>Case 1: An 85-year-old man underwent hemodialysis for progressive renal failure 4 months after right laparoscopic radical nephroureterectomy. Case 2: A 73-year-old man underwent hemodialysis after two laparoscopic radical nephroureterectomies for recurrent urothelial carcinoma. In both cases, enfortumab vedotin was administered due to postoperative recurrence and progression despite platinum-based chemotherapy and pembrolizumab. Partial response and disease progression were observed in cases 1 and 2, respectively. Adverse events included a mild skin rash in both patients and neutropenia in Case 1, both of which resolved with symptomatic treatment.</p>\n </section>\n \n <section>\n \n <h3> Conclusion</h3>\n \n <p>The efficacy and safety of enfortumab vedotin in patients with metastatic urothelial carcinoma, and end-stage renal disease undergoing hemodialysis, were confirmed.</p>\n </section>\n </div>","PeriodicalId":52909,"journal":{"name":"IJU Case Reports","volume":"7 4","pages":"324-328"},"PeriodicalIF":0.0000,"publicationDate":"2024-05-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11221941/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"IJU Case Reports","FirstCategoryId":"1085","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1002/iju5.12736","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"Medicine","Score":null,"Total":0}

引用次数: 0

Abstract

Introduction

Few studies have reported on administering enfortumab vedotin to patients with metastatic urothelial carcinoma and end-stage renal disease requiring hemodialysis.

Case presentation

Case 1: An 85-year-old man underwent hemodialysis for progressive renal failure 4 months after right laparoscopic radical nephroureterectomy. Case 2: A 73-year-old man underwent hemodialysis after two laparoscopic radical nephroureterectomies for recurrent urothelial carcinoma. In both cases, enfortumab vedotin was administered due to postoperative recurrence and progression despite platinum-based chemotherapy and pembrolizumab. Partial response and disease progression were observed in cases 1 and 2, respectively. Adverse events included a mild skin rash in both patients and neutropenia in Case 1, both of which resolved with symptomatic treatment.

Conclusion

The efficacy and safety of enfortumab vedotin in patients with metastatic urothelial carcinoma, and end-stage renal disease undergoing hemodialysis, were confirmed.

Abstract Image

查看原文本刊更多论文

血液透析转移性尿路上皮癌患者使用恩福单抗维多汀的初步经验：两份病例报告。

导言：很少有研究报道对转移性尿路上皮癌和需要血液透析的终末期肾病患者使用恩福单抗韦多汀：病例 1：一名 85 岁的男性在接受右腹腔镜根治性肾切除术 4 个月后，因进展性肾衰竭而接受了血液透析。病例 2：一名 73 岁的男性因复发性尿路上皮癌接受两次腹腔镜根治性肾切除术后，接受了血液透析。尽管接受了铂类化疗和彭博利珠单抗治疗，但由于术后复发和病情进展，两例患者均接受了恩福单抗维多汀治疗。病例1和病例2分别出现部分应答和疾病进展。不良反应包括两名患者出现轻度皮疹，病例1出现中性粒细胞减少，这两种情况在对症治疗后均缓解：结论：恩福单抗韦多汀对转移性尿路上皮癌和接受血液透析的终末期肾病患者的疗效和安全性得到了证实。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊